AC-4-130 treatment can inhibit proliferation and clonogenic growth in both AML cell lines and primary AML patient cells with IC50 between 1.6 to 4.9 μM but less toxicity against healthy CD34+ cells with IC50 between 6.3 to 7.6 μM [100]. This evidence concerns the gene CD34 and acute myeloid leukemia.